



**HTG Molecular**

*You're invited to*

## ***HTG's virtual Lymphoma Advisory Board Meeting***

As a leading expert in Lymphoma, it gives me great pleasure to invite you to participate in HTG's next *virtual Lymphoma Advisory Board Meeting*, where together we will focus on innovating molecular testing; targeting improvements in patient care and clinical outcomes for hematological diseases with a particular focus on aggressive lymphomas.

**Virtual Lymphoma Advisory Board Meeting on September 30<sup>th</sup> 2020, 4 - 5.30 pm CET**

Confirmed speakers\*:

- **Molecular features of MYC+ only aggressive B-cell lymphomas other than Burkitt lymphoma**  
*Prof. Leticia Quintanilla-Fend, University Hospital Tuebingen, Germany*
- **Analysis of the tumor microenvironments in follicular lymphoma with gene expression profiling: importance of the Th17 axis for lenalidomide sensitivity**  
*Prof. Alexandar Tzankov, University Hospital Basel, Switzerland*
- **Predicting probable MHG cases from DLBCLs from HTG panel data**  
*Dr. Sharon Barrans HMDS & Dr. John Davies University of Leeds, UK*
- **Cross-platform comparison of molecular tests for Cell-of-origin classification of diffuse large B-cell lymphoma**  
*Dr. Julia Richter, University Hospital Schleswig-Holstein Kiel, Germany*

\*The final agenda with all confirmed speakers will be available by September 20th.

I hope you consider being part of this exciting event.

You can register in the meeting by email to [sari.nousiainen@bionordika.fi](mailto:sari.nousiainen@bionordika.fi) or [mirja.heinonen@bionordika.fi](mailto:mirja.heinonen@bionordika.fi)

On behalf of HTG Molecular Diagnostics and BioNordika,

*Sari Nousiainen*

Sari Nousiainen  
Managing Director of BioNordika Oy